Home » 2019 » August » 10

Party City to divest Canadian business to Canadian Tire for $131m

Party City to divest Canadian business to Canadian Tire for $131m

Canadian Tire Corporation (CTC) has signed an agreement with Party City, a US-based retail chain of party stores, to purchase the latter’s Canadian business for C$174.4 million ($131 million). The acquisition will help Canadian Tire become Canada’s leading party supply and celebration destination. Party City with 65 Canadian retail stores in seven provinces is a […]

Table reservation platform Dineout acquires Binge Digital

Table reservation platform Dineout acquires Binge Digital

Dineout acquisition of Binge Digital : Dineout, an Indian restaurant technology solutions company owned by Times Internet, has acquired Delhi-based food technology platform Binge Digital. Dineout acquisition price for Binge Digital has not been disclosed. Dineout acquires Binge Digital The acquisition, which is said to support Dineout’s new digital menu product – Dine-In, marks the […]

ORIC Pharmaceuticals raises $55m to advance cancer resistance drugs

ORIC Pharmaceuticals raises $55m to advance cancer resistance drugs

US oncology company ORIC Pharmaceuticals has raised $55 million through a Series D financing round to advance its pipeline of cancer resistance drugs, as per the latest pharma industry news. The financing brings the total capital raised by the San Fransisco-based ORIC Pharmaceuticals to more than $175 million. Leading the Series D financing round of the […]

The post ORIC Pharmaceuticals raises $55m to advance cancer resistance drugs appeared first on PharmaNewsDaily.com.

Dynacure’s centronuclear myopathies drug DYN101 gets FDA orphan drug designation

Dynacure’s centronuclear myopathies drug DYN101 gets FDA orphan drug designation

French pharma company Dynacure has secured orphan drug designation for its investigational antisense drug DYN101 from the US Food and Drug Administration (FDA) for the treatment of Centronuclear Myopathies (CNM). DYN101, which is designed to modulate the expression of dynamin 2 (DNM2), will undergo its first human clinical trial in the form of the Unite-CNM […]

The post Dynacure’s centronuclear myopathies drug DYN101 gets FDA orphan drug designation appeared first on PharmaNewsDaily.com.

Windgap Medical, ALK-Abello forge partnership for epinephrine autoinjector

Windgap Medical, ALK-Abello forge partnership for epinephrine autoinjector

Windgap Medical has forged a partnership with ALK-Abello to commercialize the former’s epinephrine autoinjector (EAI) for the treatment of anaphylactic shock. As per the agreement, ALK-Abello will have exclusive, worldwide sales and distribution rights for the Windgap epinephrine autoinjector. For this, ALK-Abello will be making up-front, technical, and sales milestone payments plus tiered royalties on […]

The post Windgap Medical, ALK-Abello forge partnership for epinephrine autoinjector appeared first on PharmaNewsDaily.com.